Abstract 179P
Background
Exercise training reduces tumour growth by increasing tumour-infiltrating T cell density in preclinical models. However, it remains unknown whether exercise training can modify intratumoural T cells in humans. Objective: To compare the effects of exercise training intervention versus control on human prostate intratumoural T cell density.
Methods
This study is a secondary analysis of a randomised controlled trial. We randomly allocated men (age >18 years) with treatment-naïve localized prostate cancer scheduled to radical prostatectomy 2:1 to exercise training intervention or control. The exercise intervention consisted of supervised, high-intensity interval bicycling four times per week from the time of randomization until prostatectomy. Intratumoural CD3+ and CD8+ T cell densities in diagnostic biopsies and post-surgical prostatectomy specimens were quantified using immunohistochemistry. Between-group differences in changes from baseline to follow-up were estimated using constrained baseline linear mixed-effect models.
Results
A total of 30 participants were included (exercise intervention, n=20; control, n=10). We found no between-group differences in changes in CD3+ (mean difference [95% Cis]: –17 [–185; 150] cells/mm2) or CD8+ (mean difference [95% CI]: –16 [–206;172] cells/mm2) T cells. Additionally, we found no statistically significant correlations between changes in T cell density and the number of attended exercise training sessions or changes in maximal oxygen consumption.
Conclusions
In this secondary analysis of a randomised controlled trial, we found no impact of exercise training on tumour-infiltrating CD3+ and CD8+ T cell density in human prostate cancer.
Clinical trial identification
Local Ethics Committee of the Capital Region of Denmark (H-18020711). All participants provided informed consent before performing any study-related procedures, and the study was preregistered at www.clinicaltrials.gov (NCT03675529).
Legal entity responsible for the study
The authors.
Funding
TrygFonden and the Lundbeck Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
63P - Single-cell RNA-seq combined with bulk RNA-seq revealed the involvement of pancreatic cancer tissue-resident macrophages in tumour progression and the immunotherapy response
Presenter: Bin Wu
Session: Poster Display session
Resources:
Abstract
64P - Gene-editing of T cells to provide resistance against macrophage-mediated suppression: setting up an in vitro model
Presenter: Rui Coelho
Session: Poster Display session
Resources:
Abstract
68P - Real-world outcomes of nivolumab and/or ipilimumab in patients with stage III-IV melanoma, MELIOR study
Presenter: Ainara Soria Rivas
Session: Poster Display session
Resources:
Abstract
69P - Dose-dependent detrimental effect of proton pump inhibitors (PPIs) on clinical outcomes from immune checkpoint inhibitors (ICI) in patients (pts) with solid tumors
Presenter: elena speziale
Session: Poster Display session
Resources:
Abstract
70P - Efficacy of PD-1 blockade plus chemotherapy in patients with oncogenic-driven non-small cell lung cancer
Presenter: Haowei Wang
Session: Poster Display session
Resources:
Abstract
71P - Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients: A systematic review and meta-analysis
Presenter: Konstantinos Lallas
Session: Poster Display session
Resources:
Abstract
72P - Concurrent local therapy (CLT) extends clinical benefit of tebentafusp (tebe) in metastatic uveal melanoma (mUM) patients (pts)
Presenter: Tristan Lim
Session: Poster Display session
Resources:
Abstract
73P - Impact of Assessment-to-Treatment Interval on the Predictive Value of PD-L1 Expression in Melanoma
Presenter: Cecilie Vestergaard
Session: Poster Display session
Resources:
Abstract
74P - Real-world impact of adjuvant anti-PD-1 therapy on survival in Danish resected stage III melanoma patients
Presenter: Marie Weitemeyer
Session: Poster Display session
Resources:
Abstract
75P - Real-world data of adebrelimab in the first-line treatment of patients with small cell lung cancer
Presenter: Yong Song
Session: Poster Display session
Resources:
Abstract